

1 **TITLE PAGE**

2

3 **TITLE:** Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a
4 primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.

5

6 **SHORT TITLE:** Immunogenicity of a third dose of COVID-19 vaccine.

7

8 **AUTHORS:** Natalia Vargas-Herrera¹, Manuel Fernández-Navarro¹, Nestor E Cabezudo², Percy Soto-
9 Becerra³, Gilmer Solís-Sánchez⁴, Stefan Escobar-Agreda¹, Javier Silva-Valencia¹, Luis Pampa-Espinoza¹,
10 Ricardo Bado-Pérez⁵, Lely Solari¹, Roger V Araujo-Castillo¹.

11

12 **AFFILIATIONS:**

13 1. Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru.

14 2. Measles and Rubella National Reference Laboratory, Centro Nacional de Salud Pública,
15 Instituto Nacional de Salud, Lima, Peru.

16 3. Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI), Seguro Social de Salud
17 del Peru (ESSALUD), Lima, Peru.

18 4. Oficina General de Investigación y Transferencia Tecnológica, Instituto Nacional de Salud,
19 Lima, Peru.

20 5. Centro Nacional de Epidemiología, Prevención y Control de Enfermedades, Ministerio de
21 Salud – Perú, Lima, Peru.

22

23 **CORRESPONDING AUTHOR:**

24 Name: Natalia Gladys Vargas Herrera

25 E-mail: nataliavh84@gmail.com

26 Address: Capac Yupanqui 1400 – Jesus Maria, Lima, Peru.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27

28 **AUTHOR CONTRIBUTIONS:** NVH, LS, and RVAC participated in the conceptualization of the study and
29 methodology design. NVH, MFN, SEA, JSV, LPE, RBP, and RVAC were involved in data collection and
30 curation. NEC conducted and supervised the methodology and performing of laboratory testing.
31 Statistical analysis was performed by PSB, GSS, and RVAC. All the authors listed participated in the
32 writing, review and editing of the manuscript.

33

34 **CONFLICT OF INTEREST:** The authors have declared that no competing interests exist.

35

36 **FINANCIAL DISCLAIMER:** Funding for this study was provided by the Instituto Nacional de Salud -
37 Peru, Lima, Perú.

38

39 **ORCID:**

40 Natalia Vargas-Herrera: <https://orcid.org/0000-0002-0948-0114>

41 Manuel Fernández-Navarro: <https://orcid.org/0000-0003-3637-2052>

42 Nestor Edwin Cabezudo: <https://orcid.org/0000-0002-3364-8212>

43 Percy Soto-Becerra: <https://orcid.org/0000-0001-5332-9254>

44 Gilmer Solis-Sanchez: <http://orcid.org/0000-0001-7084-088X>

45 Stefan Escobar-Agreda: <https://orcid.org/0000-0002-8355-4310>

46 Javier Silva-Valencia: <https://orcid.org/0000-0002-5982-2821>

47 Luis Pampa-Espinoza: <https://orcid.org/0000-0002-2392-587X>

48 Ricardo Bado-Perez: <https://orcid.org/0000-0001-7994-583X>

49 Lely Solari: <https://orcid.org/0000-0002-8041-8807>

50 Roger V. Araujo-Castillo: <https://orcid.org/0000-0002-3740-1962>

51 **ABSTRACT**

52 **Background:** The administration of a third (booster) dose of COVID-19 vaccines in Peru initially
53 employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with
54 healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and
55 elderly people previously immunized with BNT162b2. This study evaluated the reactogenicity and
56 immunogenicity of the “booster” dose in these two groups in Lima, Peru.

57 **Methods:** We conducted a prospective cohort study, recruiting participants from November to
58 December of 2021 in Lima, Peru. We evaluated immunogenicity and reactogenicity in HCW and
59 elderly patients previously vaccinated with either two doses of BBIBP-CorV (heterologous regimen)
60 or BNT162b2 (homologous regimen). Immunogenicity was measured by anti-SARS-CoV-2 IgG
61 antibody levels immediately before boosting dose and 14 days later. IgG geometric means (GM) and
62 medians were obtained, and modeled using ANCOVA and quantile regressions.

63 **Results:** The GM of IgG levels increased significantly after boosting: from 28.5 ± 5.0 AU/mL up to
64 486.6 ± 1.2 AU/mL ($p < 0.001$) which corresponds to a 17-fold increase. The heterologous vaccine
65 regimen produced higher GM of post-booster anti-SARS-CoV-2 IgG levels, eliciting a 13% fold
66 increase in the geometric mean ratio (95%CI: 1.02-1.27) and a median difference of 92.3 AU/ml
67 (95%CI: 24.9-159.7). Both were safe and well tolerated. Previous COVID-19 infection was also
68 associated with higher pre and post-booster IgG GM levels.

69 **Conclusion:** Although both boosting regimens were highly immunogenic, two doses of BBIBP-CorV
70 boosted with BNT162b2 produced a stronger IgG antibody response than the homologous BNT162b2
71 regimen in the Peruvian population. Additionally, both regimens were mildly reactogenic and well-
72 tolerated.

73

74 **KEYWORDS:** SARS-CoV-2; COVID-19; COVID-19 Vaccines; BNT162 Vaccine; COVID-19 Serological
75 Testing; Immunogenicity, Vaccine; Adverse Drug Reaction; Peru. (Source: MeSH)

76 INTRODUCTION

77

78 The first case of COVID-19 was confirmed in Peru on March 6th, 2020 (1). Since then, almost 3,5
79 million COVID-19 cases and more than 200,000 deaths have been reported (2), making Peru one of
80 the countries with the highest death toll due to COVID-19 in the world (3). In February 2021, in the
81 midst of a very intense second wave of COVID-19, the healthcare workers (HCW), police and military
82 personnel received the BBIBP-CorV (Sinopharm) inactivated SARS-CoV-2 vaccine (4). In May 2021,
83 vaccination started on people 60 years and older with the BNT162b2 (Pfizer-BioNTech) mRNA
84 vaccine, and subsequently the vaccination program was extended to the younger population (5)
85 according to vaccine availability, using mainly BBIBP-CorV and ChAdOx1 nCoV-19 (Oxford-
86 AstraZeneca) in under 40s. All regimens consisted of two doses of vaccines, at least 21 days apart.

87

88 In October 2021, the Peruvian Ministry of Health (MINSa) approved the administration of third
89 vaccine “booster” doses (6) with BNT162b2. HCWs and people 60 years and older were again
90 prioritized to be vaccinated. With the arrival of the Omicron variant in December 2021, all adults and
91 children above 12 with comorbidities were eligible for the booster dose. Strategies for vaccination
92 against COVID-19 in Peru are permanently being reviewed and updated according to the results of
93 their evaluation. It is important to evaluate the safety and effectiveness of all the vaccination
94 regimens mandated by the MINSa. The aim of our study is to evaluate the reactogenicity and
95 immunogenicity of the third “booster” dose with BNT162b2 in people primarily vaccinated with
96 BBIBP-CorV or BNT16b2 in Lima, Peru.

97

98

99 MATERIALS AND METHODS

100

101 Design, setting and population

102 We performed a prospective cohort study in individuals who were administered a BNT162b2 booster
103 dose according to Peruvian COVID-19 vaccination guidelines. The study population included
104 participants aged 18 years and older who had previously received two doses of COVID-19 vaccines 5
105 to 12 months before. The population comprised two groups: People initially vaccinated with 2 doses
106 of BNT162b2 (Pfizer-Biotech), mainly individuals aged 60 years and older; and people vaccinated with
107 2 doses of BBIBP-CorV (Sinopharm), mostly HCWs of any profession.

108
109 Participants were excluded if, at the time of enrollment, they had active COVID-19 symptoms, allergy
110 to the BNT162b2 vaccine, or reported pregnancy. Participants who had received more than two
111 doses of any COVID-19 vaccine, or received the initial doses abroad were also excluded, as well as
112 participants who did not receive the booster dose within 24 hours after enrollment. Sampling was
113 carried out in a consecutive non-probabilistic manner in four vaccination centers in Lima that were
114 specifically authorized to administer the booster dose. Sample size was calculated to estimate the
115 geometric mean of the difference between IgG levels before and after the vaccine booster.
116 Considering a difference of IgG levels of 1.09 AU/ml \pm 1.00 (7), a precision of one tenth of the mean,
117 and a 95% confidence interval, the sample size was 387 subjects. Half that sample size yielded >99%
118 power to test if IgG ratios after boosting were different from 1, including a Bonferroni correction for
119 ten simultaneous comparisons.

120
121 **Study procedures**
122 Subjects meeting selection criteria were invited to participate in the study and signed an informed
123 consent form. Clinical and demographic data were registered in a written form, and a 5 ml blood
124 sample was drawn from each participant before receiving the booster dose. Participants were invited
125 for a second visit 14 days after the booster dose and the procedures were repeated.

126

127 The main outcome was immunogenicity, assessed through SARS-CoV-2 anti-spike and anti-
128 nucleoprotein IgG antibodies levels. These were measured using the iFlash-SARS-CoV IgG assay
129 (Shenzen YHLO Biotech Co., Ltd, China), a paramagnetic particle chemiluminescent immunoassay
130 (CLIA) using the Immunoassay Analyzer (8). No lower or upper top values were specified for this
131 assay, although a 10 AU/ml cut-off for positivity point was provided. Test details are provided in **S1**
132 **Appendix**. Sample analysis was performed at the Measles and Rubella National Reference Laboratory
133 of the Instituto Nacional de Salud – Peru.

134
135 Other variables analyzed were gender, age group (according to the World Health Organization
136 classification), presence and number of comorbidities (high blood pressure, diabetes mellitus,
137 obesity, asthma, chronic obstructive pulmonary disease, cancer, cardiovascular diseases, others),
138 prior COVID-19 infection (defined as having a prior positive antigenic or molecular test), time in
139 months between the second vaccine dose and the booster dose, time in days between first and
140 second blood sample, and type of primary vaccine regimen (BNT162b2 or BBIBP-CorV).

141
142 Safety assessment included the evaluation of the presence of local and systemic adverse reactions
143 (AR) including pain in the injection site, malaise, headache, drowsiness, fever and other events after
144 the BNT162b2 booster dose in both groups. Depending on AR intensity, these were classified as mild
145 or severe according to the Common Terminology Criteria for Adverse Events (CTCAE) (9).
146 Hospitalizations or deaths until second visit were also recorded.

147 148 **Statistical analysis**

149 Categorical variables were described using absolute and relative frequencies, while numerical
150 variables were reported using medians and interquartile ranges (IQR). IgG levels were additionally
151 characterized by geometric means (GM) and geometric standard deviations (GSD). Study variables
152 were compared according to follow-up status, primary vaccine regimen, and adverse reaction

153 presence, using chi-squared and Fisher's exact test for categorical variables, and Mann-Whitney U
154 test for numerical variables. Only participants that returned for the second visit were included in the
155 reactogenicity and immunogenicity analysis. Crude and Adjusted Poisson regression models with
156 robust standard errors were constructed in order to estimate relative risks (RR) for developing
157 adverse reactions.

158
159 For the immunogenicity analysis, comparison between IgG levels before and after vaccine boosting
160 was performed using Wilcoxon Sign Rank test and paired T test for GMs with unequal variances.
161 Bivariate association between the study variables and IgG levels before/after boosting was evaluated
162 two ways: IgG medians were contrasted using Mann-Whitney or Kruskal Wallis tests, while GMs
163 were compared using Student T or F test for geometric means. In order to model IgG values after
164 vaccine booster, two methods were employed: quantile regression to the median in order to
165 evaluate changes in absolute IgG values; and an ANCOVA approach using IgG geometric means and
166 exponentiated coefficients to evaluate changes in terms of mean fold increase. Robust standard
167 errors were used in both to handle heteroskedasticity of residuals.

168
169 All multivariable models were adjusted per age, sex, comorbidity presence, prior COVID-19 infection,
170 time between second and booster dose, vaccine booster regimen, time between first and second
171 serum sample, and IgG levels before booster. The natural logarithm form of the latter was used in an
172 attempt to normalize its distribution. Only in the immunogenicity analysis after booster, continuous
173 numerical variables were modeled using restricted cubic splines in order to handle non-linearity.
174 Spline knots were set according to Harrell's criteria (10). We demonstrated the adequacy of knots
175 selection through the inspection of partial residual plots and comparing AIC between different
176 spline's parameterizations. All confidence intervals were calculated at 95%, and significant p-values
177 were set at 0.05. All the statistical analyses were performed using Stata v.16 (College Station, TX:
178 StataCorp LLC. 2019).

179

180 **Ethical considerations**

181 The study protocol was approved by the National Institute of Health's Institutional ethics committee
182 (approval code: OI-35-21) and all participants signed a voluntary Informed Consent Form.

183

184

185 **RESULTS**

186

187 **Baseline characteristics**

188 Between November 4 and December 17, 2021, 462 individuals were enrolled. Two participants were
189 excluded for having received their initial vaccine doses abroad (Moderna, mRNA-1273), one for
190 having severe immunosuppression, one who received the initial two doses more than 12 months
191 ago, and one who did not receive the booster dose at all. Of the 457 participants who fulfilled the
192 selection criteria, 285 (62.4%) returned for the second blood sample collection and were eligible for
193 the immunogenicity/reactogenicity analysis (**Figure 1**). Baseline and demographics characteristics
194 were similar between the group that completed two blood samples and the group lost to follow up
195 (**S1 Table**).

196

197 **Figure 1:** Participation Flowchart.

198

199 Patients included had a median age of 46 years (IQR: 36-60) and 190 (66.7%) were female; 214
200 (75.1%) reported at least one comorbidity and 84 (29.5%) had prior COVID-19 infection. Regarding
201 boosting, time between second and third dose oscillated from 5 to 8 full months with a median of
202 220 days. Median time between first and second blood draw was 15 days (IQR: 14-15). Patients were
203 grouped according to primary vaccine regimen, 56 (19.6%) were primed with BNT162b2 and
204 therefore received a homologous boosting, while 229 (80.4%) were primed with BBIBP-CorV,

205 resulting in a heterologous booster (**Table 1**). There were some statistically significant differences
 206 between both groups. The group primed with BNT162b2 has a median age of 67 compared with 43 in
 207 the BBIBP-CorV group ($p < 0.001$); this is the result of the national vaccination program that provided
 208 BNT162b2 to elderly population, while BBIBP-CorV was destined to healthcare workers. Other
 209 differences that arose from this vaccination strategy were differences in sex, since there are more
 210 female healthcare workers; comorbidities, since they are more prevalent in elders; and time
 211 between the second dose and booster, since national vaccination started with BBIBP-CorV in
 212 healthcare workers, before expanding to people age 60 and older. On the other hand there were no
 213 differences by prior COVID-19 infection, or time between blood samples (**Table 1**).

214

215 **Table 1:** Participant Characteristics according to primary vaccine regimen (N=285).

	(BNT162b2 x 2) + BNT162b2 N=56 n (%) Median [IQR]	(BBIBP-CorV x 2) + BNT162b2 N=229 n (%) Median [IQR]	Total N=285 n (%) Median [IQR]	p-value
Age (years)	67 [62; 73]	43 [34; 53]	46 [36; 60]	<0.001†
Age Group				
18-29 years old	0 (0.0)	23 (10.0)	23 (8.1)	<0.001††
30- 59 years old	6 (10.7)	183 (79.9)	189 (66.3)	
60 plus years old	50 (89.3)	23 (10.0)	73 (25.6)	
Gender				
Female	28 (50.0)	162 (70.7)	190 (66.7)	0.003†
Male	28 (50.0)	67 (29.3)	95 (33.3)	
Comorbidity				
No Comorbidities	28 (50.0)	186 (81.2)	214 (75.1)	<0.001†
Presence of Comorbidities	28 (50.0)	43 (18.8)	71 (24.9)	
Number of Comorbidities				
No Comorbidities	28 (50.0)	186 (81.2)	214 (75.1)	<0.001†
One Comorbidity	22 (39.3)	39 (17.0)	61 (21.4)	
Two or more Comorbidities	6 (10.7)	4 (1.8)	10 (3.5)	
List of Comorbidities				
High Blood pressure	15 (26.8)	14 (6.1)	29 (10.2)	<0.001†
Diabetes Mellitus	8 (14.3)	9 (3.9)	17 (6.0)	0.003†
Obesity	0 (0.0)	7 (3.1)	7 (2.5)	0.352††
Asthma/COPD	2 (3.6)	10 (4.4)	12 (4.2)	1.000††
Cancer (any type)	3 (5.4)	2 (0.9)	5 (1.8)	0.054††
Cardiovascular Disease	0 (0.0)	2 (0.9)	2 (0.7)	1.000††
Others	7 (12.5)	5 (2.2)	12 (4.2)	0.001†
Prior COVID-19 Infection				
No	45 (80.4)	156 (68.1)	201 (70.5)	0.072†
Yes	11 (19.6)	73 (31.9)	84 (29.5)	

Time until booster dose (months)				
5	33 (58.9)	0 (0.0)	33 (11.6)	<0.001††
6	20 (35.7)	58 (25.3)	78 (27.4)	
7	3 (5.4)	156 (68.1)	159 (55.8)	
8	0 (0.0)	15 (6.6)	15 (5.3)	
Adverse Reactions after booster				
No	13 (23.2)	21 (9.2)	34 (11.9)	0.004†
Yes	43 (76.8)	208 (90.8)	251 (88.1)	
Number of Adverse Reactions				
None	13 (23.2)	21 (9.2)	34 (11.9)	<0.001†
One	26 (46.4)	78 (34.1)	104 (36.5)	
Two or more	17 (30.4)	130 (56.8)	147 (51.6)	
Adverse Reaction occurred				
Local pain	43 (76.8)	199 (86.9)	242 (84.9)	0.058†
Malaise	11 (19.6)	82 (35.8)	93 (32.6)	0.021†
Headache	6 (10.7)	73 (31.9)	79 (27.7)	0.002†
Drowsiness	3 (5.4)	40 (17.5)	43 (15.1)	0.022††
Fever	6 (10.7)	35 (15.3)	41 (14.4)	0.382†
Others	1 (1.8)	53 (23.1)	54 (19.0)	<0.001††
Time between 1st and 2nd sample (days)				
	14 [14; 17]	15 [14; 15]	15 [14; 15]	0.686‡

IQR: Interquartile range. IgG: Immunoglobulin G. AU/ml: Arbitrary units per ml.

†Chi Square test. ††Fisher's Exact test. ‡Mann-Whitney U test.

216

217 **Reactogenicity**

218 Among the 285 participants, 251 (88.1%) reported an adverse reaction after booster administration,
 219 all of them mild: 244 (85.3%) reported local pain at the injection site, 94 (32.9%) malaise, 79 (27.6%)
 220 headache, 43 (15%) drowsiness, 41 (14.3%) fever, and 54 (18.9%) reported other adverse reactions
 221 including diarrhea, nausea, vomiting, palpitations, neck/back pain, and one participant reported
 222 menstrual cycle changes. In the bivariate analysis, younger age, being female, and having received a
 223 heterologous booster were associated with a higher proportion of adverse reactions (**S2 Table**). In
 224 the adjusted regression model, the only characteristic that remained associated was sex: female
 225 participants were 13% more likely to develop adverse reactions than male participants (RR 1.13;
 226 95%CI 1.02-1.26) (**Table2**).

227

228 **Table 2:** Regression Models using presence of adverse reactions to the vaccine booster as outcome
 229 (N=285).

	Crude Models	Adjusted Model
--	---------------------	-----------------------

	RR (95% CI)	p-value*	RR (95% CI)	p-value**
Age Group				
18-29 years old	1.26 (1.12; 1.41)	<0.001	1.16 (0.97; 1.38)	0.102
30- 59 years old	1.13 (1.00; 1.28)	0.054	1.04 (0.88; 1.23)	0.662
60 plus years old	Reference		Reference	
Gender				
Female	1.15 (1.03; 1.28)	0.011	1.12 (1.01; 1.25)	0.036
Male	Reference		Reference	
Comorbidity				
No Comorbidities	Reference		Reference	
Presence of Comorbidities	0.93 (0.83; 1.04)	0.189	0.97 (0.85; 1.11)	0.654
Prior COVID-19 Infection				
No	Reference		Reference	
Yes	1.08 (0.99; 1.17)	0.068	1.03 (0.94; 1.13)	0.541
Time until booster dose (months)				
For each month	1.03 (0.97; 1.08)	0.338	0.92 (0.85; 1.00)	0.059
IgG Titers before booster				
For each natural logarithm	1.01 (0.95; 1.08)	0.684	1.05 (0.97; 1.13)	0.203
Vaccine Booster Regimen				
(BNT162b2 x 2) + BNT162b2	Reference		Reference	
(BBIBP-CorV x 2) + BNT162b2	1.18 (1.02; 1.37)	0.028	1.26 (0.97; 1.63)	0.079

RR: Risk ratio. 95%CI: 95% Confidence Interval. IgG: Immunoglobulin G.

* Poisson regression with robust variance, crude models.

** Poisson regression with robust variance, adjusted per all listed variables.

230

231 Baseline and post-booster immunogenicity

232 When comparing IgG levels pre versus post booster in the whole group, a marked difference was
 233 observed (**Figure 2**). The GM of IgG levels increased significantly after boosting: from 28.5±5.0 AU/mL
 234 up to 486.6±1.2 AU/mL (paired T test: p<0.001) which corresponds to a 17-fold increase. This was
 235 also observed for the median: from 29.1 AU/mL (8.4; 93.1) up to 501.9 AU/mL (446.8; 545.4)
 236 (Wilcoxon signed rank test: p<0.001).

237

238 **Figure 2:** A) Density chart showing IgG levels (AU/ml) before and after vaccine booster for the entire
 239 sample. B-F) Spaghetti and box plots showing IgG levels (AU/ml) before and after vaccine booster for
 240 the entire sample (B), and categorized by vaccine combination (C), by prior COVID-19 infection (D),
 241 by sex (E), and by presence of comorbidities (F).

242

243 Regarding COVID-19 baseline humoral status, people aged 60 and older had a higher GM (64.0+/-4.9
 244 AU/ml) than people 18-29 years old (22.9+/-5.4 AU/ml) and 30-59 years old (21.5+/-4.5 AU/ml).
 245 However, this trend was reversed for IgG levels after boosting: people 18-29 years old, and 30-59
 246 years old had the higher GMs (518.9+/-1.1 AU/mL and 505.3+/-1.1 AU/mL respectively) compared
 247 with people aged 60 years and older (432.3+/-1.2 AU/mL). This trend was also observed when aged
 248 was analyzed as a continuous variable (**Table 3, Figure 3**).

249
 250 **Table 3:** IgG Titers (AU/ml) before (baseline) and after receiving the COVID-19 vaccine booster dose
 251 (N=285).

	Baseline Geometric Mean (GSD)	p-value*	After the booster Geometric Mean (GSD)	p-value*
Age Group				
18-29 years old	22.9 (5.4)	<0.001	518.9 (1.1)	<0.001
30-59 years old	21.5 (4.5)		505.3 (1.1)	
60 plus years old	64.0 (4.9)		432.3 (1.2)	
Gender				
Female	26.1 (4.8)	0.200	488.8 (1.2)	0.511
Male	34.1 (5.3)		482.2 (1.2)	
Comorbidity				
No Comorbidities	27.7 (4.8)	0.629	497.9 (1.1)	<0.001
Presence of Comorbidities	31.1 (5.9)		453.8 (1.2)	
Number of Comorbidities				
No comorbidities	27.7 (4.8)	0.455	497.9 (1.1)	<0.001
One comorbidity	28.5 (5.6)		456.7 (1.2)	
Two or more comorbidities	53.5 (8.2)		436.2 (1.2)	
Prior COVID-19 infection				
No Infection	20.1 (4.9)	<0.001	473.5 (1.2)	<0.001
Prior Infection	66.0 (3.9)		519.2 (1.1)	
Time until booster dose (months)				
5	112.6 (2.9)	<0.001	424.3 (1.2)	
6	29.7 (4.7)		463.4 (1.2)	
7	19.8 (4.7)		511.4 (1.1)	<0.001
8	55.2 (6.5)		499.7 (1.1)	
Vaccine Booster Regimen				
(BNT162b2 x 2) + BNT162b2	99.5 (3.1)	<0.001	416.0 (1.2)	<0.001
(BBIBP-CorV x 2) + BNT162b2	21.0 (4.8)		505.6 (1.1)	

IgG: Immunoglobulin G. AU/ml: Arbitrary units per ml. GSD: geometric standard deviation.

* Student T or F test for geometric means.

252

253 **Figure 3:** Bivariate Scatter plots plus linear fit lines with 95% confidence intervals. IgG levels (AU/ml)
254 after vaccine booster (logarithm scale) are shown on the y-axis of all graphics. Numeric variables in
255 the x-axis are displayed using restricted cubic B-splines functions with the spline knots set according
256 to Harrell's criteria. The x-axis displays: IgG levels before booster in a logarithm scale (A), age in years
257 (B), time between second the third vaccine dose in months (C), and time between first and second
258 blood sample in days (D).

259
260 Baseline levels were not different by presence of comorbidities, but after booster levels were lower
261 in people presenting them: 453.8 ± 1.2 AU/mL versus 497.9 ± 1.1 AU/mL ($p < 0.001$). A prior COVID-19
262 infection was associated with a higher GM of baseline levels: 66.0 ± 3.9 AU/mL versus 20.1 ± 4.9 AU/mL
263 ($p < 0.001$), and also with higher post-booster levels: 519.2 ± 1.1 AU/mL versus 473.5 ± 1.2 AU/mL
264 ($p < 0.001$). There were no differences in pre o post booster IgG levels by gender (**Table 3, Figure 2**).

265
266 Baseline IgG levels showed a trend towards higher values at shorter periods of time between the
267 second dose and boosting. On the contrary, post-booster IgG levels tend to increase with longer
268 periods of time, except for the 8th month, when IgG levels started to decrease. Regarding time
269 between first and second blood sample, post-booster IgG antibody levels increased sharply until day
270 15th, then progressively decreased until reaching a steady state ($p = 0.003$) (**Table 3, Figure 3**).

271
272 The homologous vaccine group had the highest GM of IgG baseline antibody levels when compared
273 to the heterologous vaccine group: 99.5 ± 3.1 AU/mL versus 21.0 ± 4.8 AU/mL ($p < 0.001$). However, this
274 relationship was reversed for post-booster IgG levels: the heterologous vaccine group presented the
275 highest GM when compared to the heterologous vaccine group: 505.6 ± 1.1 AU/mL versus 416.0 ± 1.2
276 AU/mL ($p < 0.001$) (**Table 3, Figure 2**). Similar associations were observed when comparisons were
277 performed using medians and IQRs (**S3 Table**).

278

279 Based on these results, two multivariable models were constructed. Both, the ANCOVA and the
 280 quantile regression models showed that prior COVID-19 infection was associated with higher post
 281 booster levels with a 6% fold increase in the geometric mean ratio (95%CI: 1.02-1.10) and a median
 282 difference of 29.1 AU/ml (95%CI: 11.5-46.7). BBIBP-CorV priming was also associated with higher
 283 post booster IgG levels, eliciting a 13% fold increase in the geometric mean ratio (95%CI: 1.02-1.27)
 284 and a median difference of 92.3 AU/ml (95%CI: 24.9-159.7) (**Table 4**). Regarding the non-linear terms
 285 of both regression models, the only significant correlation was between higher IgG levels before
 286 booster with higher levels post-booster, as seen in **Figure 4**. Associations with age, gender,
 287 comorbidities, time until booster, and time until second sample disappeared after adjustment.
 288 Individual coefficients for each spline of the non-linear terms are shown in **S4 and S5 Tables**.

289

290 **Table 4:** Adjusted Regression Models using IgG levels (AU/ml) after vaccine booster as outcome
 291 (N=285).

	Multivariable Linear Regression		Multivariable Quantile Regression	
	GMR (95% CI)	p-value ^a	MD (95% CI)	p-value ^a
Age (years)				
(Non-linear term) ^b	*	0.585 ^c	*	0.080
Gender				
Female	Reference		Reference	
Male	1.01 (0.97; 1.04)	0.650	5.39 (-7.68; 18.46)	0.417
Comorbidity				
No Comorbidities	Reference		Reference	
Presence of Comorbidities	0.98 (0.94; 1.03)	0.460	1.88 (-14.24; 17.99)	0.819
Prior COVID-19 Infection				
No	Reference		Reference	
Yes	1.06 (1.02; 1.10)	0.004	29.11 (11.49; 46.73)	0.001
Time until booster dose (days)				
(Non-linear term) ^b	*	0.084 ^c	*	0.281
Vaccine Booster Regimen				
(BNT162b2 x 2) + BNT162b2	Reference		Reference	
(BBIBP-CorV x 2) + BNT162b2	1.13 (1.01; 1.27)	0.041	92.3 (24.90; 159.7)	0.007
Time between 1st and 2nd sample				
(Non-linear term) ^b	*	0.055 ^c	*	0.305
Natural Log of IgG titers before Booster				
(Non-linear term) ^b	*	<0.001 ^c	*	0.003

IgG: Immunoglobulin G. AU/ml: Arbitrary units per ml. GMR: Adjusted Geometric Mean Ratio. MD: Adjusted Median Difference. 95%CI: 95% Confidence Interval.

a) All p-values were obtained using a robust standard error estimator to address heteroskedasticity.

b) The non-linear effect of age, time until booster dose, time between 1st and 2nd sample and natural log of IgG titers before booster in multivariable linear regression are shown in **Figure 4**.

c) p-values for multiple coefficients of B-splines basis functions were tested using a heteroskedasticity version of F-Statistic for a joint hypothesis testing.

* Details about coefficients for B-splines are show in **Supplementary Tables 2 and 3**.

292

293 **Figure 4:** Predicted IgG levels (AU/ml) after vaccine booster (logarithm scale) with 95% confidence
294 intervals obtained from a multivariate linear model using Geometric Means and robust standard
295 errors (y-axis). Numeric variables in the x-axis were treated as restricted cubic B-splines functions
296 with the spline knots set according to Harrell's criteria. The x-axis displays IgG levels before booster
297 in a logarithm scale (A), age in years (B), time between second the third vaccine dose in months (C),
298 and time between first and second blood sample in days (D).

299

300

301 **DISCUSSION**

302 In this prospective cohort study, we report the humoral immunogenicity of a BNT162b2 vaccine
303 booster in persons having been primarily vaccinated with either two doses of BBIBP-CorV or
304 BNT162b, as well as the reactogenicity produced. To our knowledge, this is the first study comparing
305 immunogenicity of these regimens in Latin America. Noteworthy, baseline antibody levels were not
306 uniformly distributed, and participants with prior COVID-19 had significantly higher levels before
307 boosting. Interestingly, baseline levels were higher for people primed with the BNT162b2 vaccine,
308 although people who received BBIBP-CorV as primary regimen have been vaccinated for a longer
309 period of time, and it was expected that their IgG levels will be lower at the moment of boosting.

310

311 Our results show that the administration of a BNT162b2 booster significantly elicited robust humoral
312 responses measured by IgG titers in all the different groups studied, regardless of their baseline
313 levels or primary regimen received. This phenomenon has been well-described, even for people
314 primed with inactivated vaccines such as BBIBP-CorV. For instance, a Peruvian one-arm study
315 reported a strong humoral response after a heterologous BNT162b2 booster in HCWs primed with

316 the inactivated BBIBP-CorV vaccine (11), even higher than the 17-fold increase found in our study. In
317 Lebanon, a prospective cohort study comparing a BNT162b2 booster versus no booster in BBIBP-
318 CorV vaccinated people, found that boosting elicited higher anti-spike IgG geometric mean titers:
319 8040 BAU/mL (95%CI: 4612–14016) versus 1384 BAU/mL (95%CI: 1063–1801) $p < 0.001$ (12).
320 However, none of these studies included more than one vaccine regime.

321
322 In our study, we found that the heterologous combination was more immunogenic than the
323 homologous one, after adjustment by age, gender, comorbidities, prior COVID-19 infection, time
324 until booster, time between samples, and baseline IgG levels. The phenomenon of higher humoral
325 response after a heterologous booster has been described in previous studies assessing different
326 COVID-19 vaccines (13-16). It has also been reported in combinations containing other inactivated
327 virus vaccines. In Chile, Vargas et al found that, in people primed with CoronaVac (Sinovac), a
328 heterologous booster with BNT162b2 or ChAdOx1 increased anti-spike IgG antibody titers more
329 strongly than the corresponding homologous booster (13).

330
331 The use of heterologous vaccine regimens for the second dose or as booster has been practiced
332 before the SARS-CoV-2 pandemic for infectious diseases such as HIV, HPV, influenza, malaria and
333 Ebola (17, 18). In the COVID-19 pandemic context, both animal and human studies that mixed
334 adenovirus and mRNA vaccines, in general showed higher antibody and T-cell responses when
335 compared to 2 doses of the same vaccine platform (19-21). The possible mechanism for the higher
336 immune responses when using different vaccine platforms could be explained by evoking different
337 immune pathways which produces stronger and longer-lasting T-cell and B-cell (both IgG and
338 neutralizing antibodies) responses (17). In the particular case of inactivated COVID-19 vaccines such
339 as BBIBP-CorV, as these contain additional SARS-CoV-2 proteins such as the nucleoprotein, the
340 protection conferred against this virus could theoretically be wider by inducing immune responses
341 beyond the spike protein. This mechanism could also reduce the immune escape of SARS-CoV-2

342 variants (14). This potential advantage could be potentiated by combining an inactivated virus
343 vaccine with an mRNA vaccine, since this last one was the most immunogenic in the COV-BOOST
344 clinical trial when used as part of a heterologous booster regimen (22).

345
346 Due to the expected waning effectiveness over time of COVID-19 vaccines, a third dose has
347 demonstrated to increase protection against SARS-CoV-2 infection, severe disease and death (23)
348 which is extremely important in a context of very transmissible variants such as Omicron (B.1.1.529)
349 and its descendant lineages BA.1 and BA.2. However, we found that antibody titers before the
350 booster inversely correlated with the titers after booster with an mRNA vaccine, which indicates that
351 short interval boosting may not provide an additional protection (24).

352
353 We also observed that participants with prior COVID-19 infection had higher IgG antibody titers post
354 booster, a finding that has been described in studies assessing immunogenicity in vaccinated people
355 with and without previous COVID-19 infection (25). This is explained by hybrid immunity to SARS-
356 CoV-2 (when vaccine-generated immunity is combined with natural immunity), which induces a
357 potent immune response that can result in 25 to 100 times higher antibody levels due to CD4⁺T and
358 memory B cells (26).

359
360 Regarding reactogenicity, our findings showed that despite most participants reporting at least one
361 adverse event, all of these were mild, and without significant differences between the homologous
362 and heterologous vaccine regimens. In addition, we found that more female participants developed
363 adverse reactions than males, which has been previously described and is explained by the fact that
364 women are known to elicit stronger innate and adaptive immune responses to foreign antigens than
365 men (27).

366

367 Some limitations in our study ought to be acknowledged. In the first place, all the participants were
368 enrolled in vaccination centers from Lima through a non-probabilistic sampling, which could affect
369 the representativeness of the general boosted population in Peru. Secondly, there was an important
370 percentage of loss of follow-up, with almost a third of the enrolled participants not returning on time
371 for their second blood sample. However, the sample size was still enough for a multivariate
372 comparison of IgG levels pre/post booster, and there were no statistically significant differences
373 between the people who completed the second visit and those who did not. An additional problem
374 was the varying time between first and second IgG measurements; although the indication was to
375 return 14 days +/-48 hours after boosting, a significant number came later, up to 28 days after
376 boosting. Finally, we measured humoral response broadly, and did not include neutralizing
377 antibodies or cellular immunity response, although binding antibody titers have been found to
378 correlate with protective efficacy (28).

379

380 On the other hand, one of the main strengths of our study is that we included a relatively large
381 number of participants with different ages that were closely followed over time and thus the data
382 obtained regarding immunogenicity and reactogenicity is reliable. We also had a reliable form of
383 measuring prior COVID-19 infection and time of initial vaccines using the Peruvian Ministry of health
384 datasets. Finally, we were extremely careful modeling the IgG levels after boosting using geometric
385 means ratios for the outcome, and applying restricted splines for non-linear numeric exposures. The
386 relevance of this study is mainly related to the information it offers about the BBIBP-CorV vaccine
387 and combinations of it, for which there is scarcity of evaluation studies. For Peru, the availability of
388 this vaccine for prioritized population such as HCW was very important in moments when other
389 platforms, such as mRNA vaccines, were only available in few countries. Confirming that people
390 receiving it as a primary regime are probably very well protected against subsequent infections with
391 subsequent vaccine doses of other vaccines, now widely available, is reassuring.

392

393 In conclusion, two doses of BBIBP-CorV boosted with one BNT162b2 dose elicited very high IgG
394 antibody responses, and three BNT162b2 doses induced a similar response. Both regimens were safe
395 and well tolerated. In addition, the antibody titers rising trend after the second vaccine dose in our
396 study indicates that subsequent boosters could be spaced and prioritized in certain populations such
397 as elderly and immunosuppressed. This reaffirms the importance of mix-and-match strategies that
398 also include inactivated vaccines in order to overcome vaccine availability obstacles.

399 **REFERENCES**

- 400 1. WHO/PAHO - Respuesta a la emergencia por COVID-19 en Perú | Pan-American Health
401 Organization [Internet]. [Cited January 25th 2022]. Available in:
402 <https://www.paho.org/es/respuesta-emergencia-por-covid-19-peru>
- 403 2. Johns Hopkins University of Medicine. Peru - COVID-19 Overview - Johns Hopkins [Internet].
404 Johns Hopkins Coronavirus Resource Center. [Cited March 22nd 2022]. Available in:
405 <https://coronavirus.jhu.edu/region/peru>
- 406 3. Herrera-Añazco P, Uyen-Cateriano A, Mezones-Holguin E, Taype-Rondan A, Mayta-Tristan P,
407 Malaga G, et al. Some lessons that Peru did not learn before the second wave of COVID-19. *Int J*
408 *Health Plann Manage*. February 2021;10.1002/hpm.3135.
- 409 4. Escobar-Agreda S, Silva-Valencia J, Rojas-Mezarina L, Vargas-Herrera J. Supervivencia de los
410 trabajadores de salud infectados por SARS-CoV-2 en el contexto de la vacunación contra la
411 COVID-19 en el Perú. *Fac Med Perú*. 2021;106-12.
- 412 5. RESOLUCION-MINISTERIAL-Nº-488-2021-MINSA-21-042269-005.pdf [Internet]. [Cited January
413 25th 2022]. Available in: [https://www.dge.gob.pe/portalnuevo/wp-](https://www.dge.gob.pe/portalnuevo/wp-content/uploads/2020/04/RESOLUCION-MINISTERIAL-N%C2%BA-488-2021-MINSA-21-042269-005.pdf)
414 [content/uploads/2020/04/RESOLUCION-MINISTERIAL-N%C2%BA-488-2021-MINSA-21-042269-](https://www.dge.gob.pe/portalnuevo/wp-content/uploads/2020/04/RESOLUCION-MINISTERIAL-N%C2%BA-488-2021-MINSA-21-042269-005.pdf)
415 [005.pdf](https://www.dge.gob.pe/portalnuevo/wp-content/uploads/2020/04/RESOLUCION-MINISTERIAL-N%C2%BA-488-2021-MINSA-21-042269-005.pdf)
- 416 6. Ministerio de Salud - Peru. Vacuna COVID-19 en el Perú [Internet]. REUNIS - Repositorio Único
417 Nacional de Información en Salud. 2022 [Cited January 25th 2022]. Available in:
418 <https://www.minsa.gob.pe/reunis/data/vacunas-covid19.asp>
- 419 7. Peled Y, Ram E, Lavee J, Segev A, Matezki S, Wieder-Finesod A, et al. Third dose of the BNT162b2
420 vaccine in heart transplant recipients: Immunogenicity and clinical experience. *J Heart Lung*
421 *Transplant*. February 2022;41(2):148-57.
- 422 8. Yokoyama R, Kurano M, Morita Y, Shimura T, Nakano Y, Qian C, et al. Validation of a new
423 automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting
424 both N and S proteins in Japan. *PLoS ONE*. March 2021;16(3):e0247711.

- 425 9. National Cancer Institute - Division of cancer Treatment & Diagnosis. Common Terminology
426 Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. [Cited April 27th
427 2022]. Available in:
428 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
- 429 10. Harrell, F.E. Regression Modeling Strategies: With applications to Linear Models, Logistic
430 Regression, and Survival Analysis. New York: Springer; 2001.
- 431 11. Hueda-Zavaleta M, Gómez de la Torre JC, Cáceres-Del Aguila JA, Muro-Rojo C, De La Cruz-Escurra
432 N, Arenas Siles D, et al. Evaluation of the Humoral Immune Response of a Heterologous
433 Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in
434 Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection. *Vaccines*. April
435 2022;10(4):502.
- 436 12. Moghnieh R, Mekdashi R, El-Hassan S, Abdallah D, Jisr T, Bader M, et al. Immunogenicity and
437 reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with
438 homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
439 *Vaccine*. November 2021;39(46):6713-9.
- 440 13. Vargas L, Valdivieso N, Tempio F, Simon V, Sauma D, Valenzuela L, et al. Serological study of
441 CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-
442 CoV-2 S antibodies [Internet]. medRxiv January 2022 [Cited February 16th 2022]. Available in:
443 <http://medrxiv.org/lookup/doi/10.1101/2022.01.14.22269289>
- 444 14. Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, et al.
445 Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two
446 doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind,
447 randomised study. *Lancet*. February 2022;399(10324):521-9.
- 448 15. Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Vichaiwattana P,
449 Thongmee T, et al. Safety and immunogenicity of heterologous and homologous inactivated and

- 450 adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.
451 Hum Vaccines Immunother. December 2022;18(1):2029111.
- 452 16. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. Homologous and
453 Heterologous Covid-19 Booster Vaccinations. N Engl J Med. March 2022;386(11):1046-57.
- 454 17. Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-and-match:
455 The concept, the efficacy and the doubts. J Med Virol. November 2021;10.1002/jmv.27463.
- 456 18. Wang S, Parker C, Taaffe J, Solórzano A, García-Sastre A, Lu S. Heterologous HA DNA vaccine
457 prime - inactivated influenza vaccine boost is more effective than using DNA or inactivated
458 vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.
459 Vaccine. July 2008;26(29-30):3626-33.
- 460 19. Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K, et al.
461 Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines
462 induce robust immune responses in mice. Nat Commun. May 2021;12(1):2893.
- 463 20. Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-
464 19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T
465 cell reactivity. medRxiv. 1 de enero de 2021;2021.05.30.21257971.
- 466 21. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et al.
467 Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1
468 nCoV-19/BNT162b2 vaccination. Nat Med. septiembre de 2021;27(9):1525-9.
- 469 22. Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity
470 of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or
471 BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
472 The Lancet. 18 de diciembre de 2021;398(10318):2258-76.
- 473 23. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of
474 BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 7 de octubre de
475 2021;385(15):1393-400.

- 476 24. Rishi R. Goel, Mark M. Painter, Kendall A. Lundgreen, Sokratis A. Apostolidis, Amy E. Baxter,
477 Josephine R. Giles, Divij Mathew et al. Efficient recall of Omicron-reactive B cell memory after a
478 third dose of SARS-CoV-2 mRNA vaccine [Internet]. bioRxiv February 2022 [Cited April 13th
479 2022]. Available in: <https://www.biorxiv.org/content/10.1101/2022.02.20.481163v1>
- 480 25. Yalçın TY, Topçu DI, Doğan Ö, Aydın S, Sarı N, Erol Ç et al. Immunogenicity of BNT162b2, BBIBP-
481 CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection - A
482 comparative study from Novi Sad, Serbia. PLoS One. 2022 Feb 2;17(2):e0263468.
- 483 26. Crotty, Shane. Hybrid immunity. Science. 2021;372(6549):1392.
- 484 27. McCartney PR. Sex-Based Vaccine Response in the Context of COVID-19. J Obstet Gynecol
485 Neonatal Nurs. September 2020;49(5):405-8.
- 486 28. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for
487 antibody as a protective correlate for COVID-19 vaccines. Vaccine. July 2021;39(32):4423-8.









Figure2







Figure3




Figure4




Figure 1